The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological drugs advances its international expansion with the opening of its first commercial office in the United States located in Boston, Massachusetts.

Experts called on to move forward rapidly at the 7th AMR Conference in Basel. Picture: ©?bamconn GmbH/Thorsten Biernath

How to stop the silent pandemic AMR was discussed by 500 experts from 13 countries at the 7th AMR Conference in Basel. At that time, in Brussels, there were two proposals on the table on how to compensate novel resistance-breaking antimicrobials, from which one got the green light in the new pharma legislation.

© Syncona

Syncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing.

Eculizumab (Soliris) is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica.  © Naingwaiwin/wikimedia.com

Roche AG has announced positive results from the non-blinded Phase III COMMODORE 1 and 2 trials at the EHA Hybrid Congress in Frankfurt, Germany.

© CGT Catapult

The world 3rd largest gene and cell therapy (CGT) cluster, the UK CGT Catapult has expanded its operations opening a subsidiary in Edinburgh.

Picture: Amarna Therapeutics

Leiden-based Amarna Therapeutics announces the appointment of Dr Henk Streefkerk as the company’s new Chief Executive Officer and Medical Director. Streefkerk has already been Amarna’s Medical Director since mid-2022.

©?PELOBiotech

At the IZB, we are right in the middle of it allas one of the leading cell culture specialists in the heart of Germany’s biotech hotspot and as a medium manufacturer in life science research.

Chris_Dormann_Coherent.jpg

“It’s obvious that the overall healthcare market will continue to grow. And photonics technology – which delivers a number of unique capabilities, like non-invasive or non-contact probing at high spatial resolution – is poised to play an ever-increasing role in this field.”

Bayer Pharmaceuticals headquarters in Berlin, © Bayer AG

Bayer boosts its gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Inc.

Multiple factors determine whether tumor cells will be eliminated by the immune system or will escape detection.© wikimedia.com/By Frontiers in Oncology - http://www.frontiersin.org/files/Articles/51138/fonc-03-00197-HTML/image_m/fonc-03-00197-g001.jpg, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=33585764

Bergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing.

,